FSTL3 protein linked to oral cancer spread via lymph nodes
CRISPR screening identifies FSTL3 as driver of oral cancer metastasis; potential target for new therapies.
Researchers used CRISPR-Cas9 gene screening to identify a protein called FSTL3 (follistatin-like 3) that helps oral squamous cell carcinoma (OSCC) cells resist death and spread to lymph nodes. Lymph node metastasis is a key driver of poor outcomes in oral cancer, and understanding the mechanisms behind it is essential for developing better treatments.
How FSTL3 enables cancer cell survival
The study found that FSTL3 activates a process called cuproptosis resistance, which allows cancer cells to evade a form of programmed cell death. By blocking this pathway, researchers observed reduced metastatic potential in OSCC cells, suggesting that FSTL3 is a critical factor in the cancer's ability to spread. The protein also promotes the recruitment of endothelial progenitor cells (EPCs), which support tumor growth and vascular development.
Implications for oral cancer prognosis and treatment
These findings may explain why some OSCC tumors are more aggressive and prone to metastasis than others. Since lymph node involvement is strongly associated with poor survival rates in oral cancer patients, therapies targeting FSTL3 or the cuproptosis pathway could potentially slow disease progression and improve outcomes. The research opens new avenues for developing biomarkers to predict metastatic risk and for designing targeted interventions.
Frequently asked questions
What is FSTL3 and why does it matter in oral cancer?
FSTL3 (follistatin-like 3) is a protein identified through CRISPR-Cas9 screening that promotes cuproptosis resistance and endothelial progenitor cell recruitment in oral squamous cell carcinoma. It enables cancer cells to evade death and spread to lymph nodes, making it a potential therapeutic target.
How does FSTL3 help cancer cells spread?
FSTL3 activates cuproptosis resistance, a mechanism that allows cancer cells to survive programmed cell death. It also recruits endothelial progenitor cells that support tumor growth and vascular development, facilitating metastasis to regional lymph nodes.
What is the clinical significance of lymph node metastasis in oral cancer?
Lymph node involvement is a major prognostic indicator in oral squamous cell carcinoma, driving poor outcomes and reduced survival rates. Understanding the molecular mechanisms behind lymph node metastasis, such as FSTL3-driven cuproptosis resistance, could lead to better treatment strategies.
Could FSTL3 be targeted therapeutically?
Yes. The study showed that blocking FSTL3-driven pathways reduced metastatic potential in OSCC cells in laboratory settings. Therapies targeting FSTL3 or cuproptosis could potentially slow cancer progression, though further development and clinical testing are needed.
